Dupilumab, biologics for younger patients with atopic dermatitis

Later this year, the U.S. Food and Drug Administration (FDA) will decide whether to approve Regeneron’s dupilumab (Dupixent) for the treatment of moderate to severe atopic dermatitis in children 6 months to 5 years old. .

If approved, the interluekin 4 and 13 (IL-4, IL-13) inhibitor biologic would become fully approved for all pediatric and adolescent age groups; it would also be the first in its class to receive approval for the youngest patients with atopic dermatitis who may be treated.

Its impact at this level may be greater than expected.

In the second part of an interview with HCP Live At the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, Amy S. Paller, MD, chair of the department of dermatology at Northwestern Feinberg School of Medicine, discussed the potential utility of dupilumab in the real world in pediatric atopic dermatitis the youngest indication.

“Although the trials didn’t include many children over the age of 2, this really reflects what we’re seeing, as we don’t like starting children in this age group on systemic treatment at all. unless we’ve given topical steroids an adequate trial dose, because sometimes good management makes a total difference for the child and the family,” Paller said.

For young children who cannot respond to standard disease management care, dupilumab could be “life-changing,” Paller said — the results for neuropsychiatric burdens, type 2 inflammatory disease progression, and risk of developing atopic diseases could be avoided if agents like dupilumab effectively treat early atopic dermatitis.

In fact, Paller noted, many illnesses related to young patients with atopic dermatitis — asthma, allergic rhinitis, food allergy, among others — are either being treated with dupilumab or under investigation for treatment with dupilumab.

“It will be important for us to try to assess, finally, if we need to start something early because atopic dermatitis is so severe, if it will be life changing in other ways as well,” Paller said. “It’s going to be very difficult to know because we can’t just start these drugs preventively, before one even gets atopic dermatitis or early on, without giving adequate trials – which can take months and months. – topical steroids.”

Comments are closed.